These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 36030299)

  • 1. A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
    Kaur U; K L A; Chauhan M; Joshi A; Das A; Kansal S; Jaisawal V; Patwardhan K; Chakrabarti SS
    Drug Saf; 2022 Oct; 45(10):1099-1109. PubMed ID: 36030299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
    Li Y; Li J; Dang Y; Chen Y; Tao C
    JMIR Public Health Surveill; 2024 Jul; 10():e51007. PubMed ID: 39008362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events.
    Noh Y; Ko HY; Kim JH; Yoon D; Choe YJ; Choe SA; Jung J; Shin JY
    Epidemiol Health; 2023; 45():e2023054. PubMed ID: 37309115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].
    Sawadogo R; Ouoba J; Ilboudo D; Tchoumbi E; Lankoandé-Haro S; Fofana S; Sombié I; Samadoulougou S; Kirakoya-Samadoulougou F
    Sante Publique; 2024 Feb; 35(6):149-159. PubMed ID: 38388395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Otorhinolaryngologic complications after COVID-19 vaccination, vaccine adverse event reporting system (VAERS).
    Shin J; Shim SR; Lee J; Ryu HS; Kim JY
    Front Public Health; 2023; 11():1338862. PubMed ID: 38269374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya.
    Amdany H; Koech B
    JBI Evid Implement; 2023 Jun; 21(2):146-155. PubMed ID: 36545897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety Analysis of the BBV152 Coronavirus Vaccine in Adolescents and Adults: Findings from a 1-Year Prospective Study in North India.
    Kaur U; Jaiswal A; Jaiswal A; Singh K; Pandey A; Chauhan M; Rai M; Kansal S; Patwardhan K; Jaisawal V; Chakrabarti SS
    Drug Saf; 2024 May; ():. PubMed ID: 38740691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study.
    Sebastian J; Gurumurthy P; Ravi MD; Ramesh M
    Ther Adv Vaccines Immunother; 2019; 7():2515135519889000. PubMed ID: 31799496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance.
    Hagos AA; Sahile Z; Ahmed W; Phanouvong S
    Glob Health Sci Pract; 2024 Feb; 12(Suppl 1):. PubMed ID: 38216210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.
    Kim S; Bea S; Choe SA; Choi NK; Shin JY
    Eur J Clin Pharmacol; 2024 Mar; 80(3):445-453. PubMed ID: 38212538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Population-Based Structures to Actively Monitor AEFIs during a Mass Immunization Campaign-A Case of Measles-Rubella and Polio Vaccines.
    Kajungu D; Nambasa V; Muhoozi M; Tusabe J; Kampmann B; Todd J
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of inactivated COVID-19 in healthy adults aged ≥ 18 years: A passive surveillance in Indonesia.
    Kaswandani N; Medise BE; Leonard E; Satari HI; Sundoro J; Hadinegoro SRH; Putra A; Angkasa PF
    PLoS One; 2023; 18(10):e0286484. PubMed ID: 37824453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
    Slingerland P; van Hunsel FPAM; Lieber T; van Balveren L; Duijster JW
    Drug Saf; 2023 Dec; 46(12):1323-1334. PubMed ID: 37882905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
    Dong G; Bate A; Haguinet F; Westman G; Dürlich L; Hviid A; Sessa M
    Drug Saf; 2024 Feb; 47(2):173-182. PubMed ID: 38062261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Adverse Events Following COVID-19 Vaccination: A Cross-sectional Study in Ibadan, Nigeria.
    Alao MA; Ogunbosi BO; Ibrahim OR; Oladokun RE; Lagunju IA
    Niger Med J; 2022; 63(3):248-258. PubMed ID: 38835530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of adverse effects following immunisation degree after the administration COVID-19 vaccine of different platforms.
    Bermawi B; Donastin A; Sari NDK; Kurniasari DW; Adriansyah AA; Ferdiansyah MA; Rofananda IF; Surya PA
    Med J Malaysia; 2024 Mar; 79(2):124-127. PubMed ID: 38553914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands.
    Ouaddouh C; Duijster JW; Lieber T; van Hunsel FPAM
    Expert Opin Drug Saf; 2024 Mar; 23(3):323-331. PubMed ID: 37796980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in Immunization Safety Monitoring - Worldwide, 2020-2022.
    Blau EF; Balakrishnan MR; Sköld H; Santhana Gopala Krishnan RS; Lundquist P; Pal S; Gidudu JF
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(49):1321-1326. PubMed ID: 38060432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following Covaxin administration among adolescents (15-18 years) - A pharmacovigilance study in a district in Northern India.
    Deb T; Kaur M; Misra S; Verma N; Sindhu N; Kairi J
    J Family Med Prim Care; 2024 Mar; 13(3):838-840. PubMed ID: 38736802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.